Kawano Kouji, Mizuno Takuya
Primo Animal Hospital Tokyo Animal Allergy Medical Center (AAMC), 1-28-7 Shakujiimachi, Nerima-Ku, Tokyo, 177-0041, Japan.
Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, Yamaguchi, 753-8515, Japan.
Vet Dermatol. 2017 Dec;28(6):583-e141. doi: 10.1111/vde.12470. Epub 2017 Aug 4.
Dermatophagoides farinae is a major and common environmental house dust mite involved in canine atopic dermatitis (CAD). A formulation of recombinant protein Der f 2 is available in Japan for immunotherapy in dogs.
HYPOTHESIS/OBJECTIVES: To evaluate the efficacy of a recombinant allergen based on Der f 2-pullulan for the treatment of cAD.
Dogs (n = 15) with atopic dermatitis were administered Der f 2 conjugated with pullulan (-P). Two dogs were eliminated because of death unrelated to the treatment during the study. The remaining 13 cases were included in the analysis. Clinical signs were evaluated with the Canine Atopic Dermatitis Lesion Index (CADLI) and pruritus levels were evaluated from 0 to 10 with a pruritus Visual Analog Scale (PVAS).
The mean ± standard deviation (SD) of CADLI [before allergen-specific immunotherapy (pre-ASIT) 21.9 ± 9.7; 60 days post-ASIT 9.8 ± 8.4 and 120 days post-ASIT 9.7 ± 8.2] and the mean ± SD of PVAS [pre-ASIT 7.2 ± 1.2; post-ASIT (60 days) 2.6 ± 2.2 and post-ASIT (120 days) 3.1 ± 2.5] significantly decreased after treatment (Dunnett's test, P < 0.05). Furthermore, the total doses of oral glucocorticoids in the two months pre-ASIT significantly decreased in comparison with two months post-ASIT (123 ± 72.6 mg vs. 70.0 ± 84.3 mg; Dunnett's test, P < 0.05).
The results indicate the effectiveness of Der f 2-P recombinant protein in the treatment of dogs with CAD and testing positive to D. farinae.
粉尘螨是参与犬特应性皮炎（CAD）的一种主要且常见的环境屋尘螨。在日本有一种重组蛋白Der f 2制剂可用于犬的免疫治疗。
假设/目的：评估基于Der f 2 - 普鲁兰多糖的重组变应原治疗CAD的疗效。
给15只患有特应性皮炎的犬施用与普鲁兰多糖结合的Der f 2（-P）。在研究期间，有2只犬因与治疗无关的死亡而被排除。其余13例纳入分析。用犬特应性皮炎皮损指数（CADLI）评估临床体征，并用瘙痒视觉模拟量表（PVAS）从0至10评估瘙痒程度。
CADLI的均值±标准差（SD）[变应原特异性免疫治疗前（pre - ASIT）为21.9±9.7；ASIT后60天为9.8±8.4，ASIT后120天为9.7±8.2]以及PVAS的均值±SD[pre - ASIT为7.2±1.2；ASIT后（60天）为2.6±2.2，ASIT后（120天）为3.1±2.5]在治疗后显著降低（Dunnett检验，P < 0.05）。此外，与ASIT后两个月相比，ASIT前两个月口服糖皮质激素的总剂量显著降低（123±72.6毫克对70.0±84.3毫克；Dunnett检验，P < 0.05）。
结果表明Der f 2 - P重组蛋白对粉尘螨检测呈阳性的CAD犬具有治疗效果。
